No CEO Reveal For Sanofi At J.P. Morgan, But Some Drug Updates
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi dodged questions about CEO succession plans at the J.P. Morgan Healthcare conference, but did confirm it filed its PCSK9 inhibitor alirocumab in the fourth quarter.